Innovation In the prognostication of chronic lymphocytic
leukemia: how far beyond TP53 gene analysis can we go?

J 2016

Innovation In the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?

POSPÍŠILOVÁ, Šárka; Lesley-Ann SUTTON; Jitka MALČÍKOVÁ; Eugen TAUSCH; Davide ROSSI et al.

Základní údaje

Originální název

Innovation In the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?

Autoři

POSPÍŠILOVÁ, Šárka; Lesley-Ann SUTTON; Jitka MALČÍKOVÁ ; Eugen TAUSCH; Davide ROSSI; Emili MONTSERRAT; Carol MORENO; Kostas STAMATOPOULOS; Gianluca GAIDANO; Richard ROSENQUIST a Paolo GHIA

Vydání

Haematologica, PAVIA, FERRATA STORTI FOUNDATION, 2016, 0390-6078

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Itálie

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 7.702

Označené pro přenos do RIV

Organizační jednotka

Středoevropský technologický institut

DOI

https://doi.org/10.3324/haematol.2015.139246

UT WoS

000379392800016

Klíčová slova anglicky

CLONAL EVOLUTION; MUTATIONS; SURVIVAL; TRIAL; PROGRESSION; IMPACT; CLL

Štítky

EDITORIAL, MEDGENET

Změněno: 29. 9. 2016 10:19, Mgr. Eva Špillingová

Anotace

V originále

T he prognostication of patients with chronic lympho- cytic leukemia (CLL) currently relies on both clinical and biological parameters (Figure 1). The prime exam- ple concerns the TP53 gene, whereby inactivation of TP53 , resulting from either a mutation or chromosome 17p deletion, is associated with a short time to progression, an early need for treatment, and an overall dismal outcome. 1,2 The presence of TP53 aberrations is also a strong predictor of treatment response, as patients carrying such lesions respond poorly to standard chemoimmunotherapy (CIT) (i.e. fludarabine, cyclophosphamide, and rituximab). 3 Although TP53 abnor- malities are infrequent at diagnosis (5%-10%), they are found in 40%-50% of advanced or therapy-refractory cases, hence underscoring the need to re-assess TP53 gene status as the dis- ease progresses and clones evolve.

Návaznosti

ED1.1.00/02.0068, projekt VaV

Název: CEITEC - central european institute of technology

NV15-30015A, projekt VaV

Název: Analýza klonální heterogenity chronické lymfocytární leukemie pomoci sekvenování nové generace genu pro B-buněčný receptor. Národní studie.

NV15-31834A, projekt VaV

Název: Vliv selekce genomických poškození na průběh chronické lymfocytární leukémie

Citovat

POSPÍŠILOVÁ, Šárka; Lesley-Ann SUTTON; Jitka MALČÍKOVÁ; Eugen TAUSCH; Davide ROSSI; Emili MONTSERRAT; Carol MORENO; Kostas STAMATOPOULOS; Gianluca GAIDANO; Richard ROSENQUIST a Paolo GHIA. Innovation In the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go? Haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2016, roč. 101, č. 3, s. 263-265. ISSN 0390-6078. Dostupné z: https://doi.org/10.3324/haematol.2015.139246.

@article{1355420,
   author = {Pospíšilová, Šárka and Sutton, LesleyandAnn and Malčíková, Jitka and Tausch, Eugen and Rossi, Davide and Montserrat, Emili and Moreno, Carol and Stamatopoulos, Kostas and Gaidano, Gianluca and Rosenquist, Richard and Ghia, Paolo},
   article_location = {PAVIA},
   article_number = {3},
   doi = {https://doi.org/10.3324/haematol.2015.139246},
   keywords = {CLONAL EVOLUTION; MUTATIONS; SURVIVAL; TRIAL; PROGRESSION; IMPACT; CLL},
   language = {eng},
   issn = {0390-6078},
   journal = {Haematologica},
   title = {Innovation In the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?},
   url = {http://www.haematologica.org/content/101/3/263.full.pdf+html},
   volume = {101},
   year = {2016}
}

TY  - JOUR
ID  - 1355420
AU  - Pospíšilová, Šárka - Sutton, Lesley-Ann - Malčíková, Jitka - Tausch, Eugen - Rossi, Davide - Montserrat, Emili - Moreno, Carol - Stamatopoulos, Kostas - Gaidano, Gianluca - Rosenquist, Richard - Ghia, Paolo
PY  - 2016
TI  - Innovation In the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?
JF  - Haematologica
VL  - 101
IS  - 3
SP  - 263-265
EP  - 263-265
PB  - FERRATA STORTI FOUNDATION
SN  - 03906078
KW  - CLONAL EVOLUTION
KW  - MUTATIONS
KW  - SURVIVAL
KW  - TRIAL
KW  - PROGRESSION
KW  - IMPACT
KW  - CLL
UR  - http://www.haematologica.org/content/101/3/263.full.pdf+html
L2  - http://www.haematologica.org/content/101/3/263.full.pdf+html
N2  - T he prognostication of patients with chronic lympho- cytic leukemia (CLL) currently relies on both clinical and biological parameters (Figure 1). The prime exam- ple concerns the TP53 gene, whereby inactivation of TP53 , resulting from either a mutation or chromosome 17p deletion, is associated with a short time to progression, an early need for treatment, and an overall dismal outcome. 1,2 The presence of TP53 aberrations is also a strong predictor of treatment response, as patients carrying such lesions respond poorly to standard chemoimmunotherapy (CIT) (i.e. fludarabine, cyclophosphamide, and rituximab). 3 Although TP53 abnor- malities are infrequent at diagnosis (5%-10%), they are found in 40%-50% of advanced or therapy-refractory cases, hence underscoring the need to re-assess TP53 gene status as the dis- ease progresses and clones evolve.
ER  -

POSPÍŠILOVÁ, Šárka; Lesley-Ann SUTTON; Jitka MALČÍKOVÁ; Eugen TAUSCH; Davide ROSSI; Emili MONTSERRAT; Carol MORENO; Kostas STAMATOPOULOS; Gianluca GAIDANO; Richard ROSENQUIST a Paolo GHIA. Innovation In the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go? \textit{Haematologica}. PAVIA: FERRATA STORTI FOUNDATION, 2016, roč.~101, č.~3, s.~263-265. ISSN~0390-6078. Dostupné z: https://doi.org/10.3324/haematol.2015.139246.

Přehled o publikaci